Dr. John Kuttesch

Hematology | Oncology
University Of New Mexico Hospitals
2211 Lomas Blvd NE, 
Albuquerque, NM 
Clinical Trials:Currently Recruiting for 3 Trials
University Of New Mexico Hospitals
2211 Lomas Blvd NE, 
Albuquerque, NM 

Overview

John Kuttesch is a Hematologist and an Oncologist practicing medicine in Albuquerque, New Mexico.

His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Embryonal Tumor with Multilayered Rosettes, Glioma, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 25 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in NM

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

University of New Mexico Hospitals
2211 Lomas Blvd NE, Albuquerque, NM 87106

Additional Areas of Focus

Dr. Kuttesch has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: March 31, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: February 27, 2026
Intervention Type: Other
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Enrollment Status: Recruiting
Publish Date: February 27, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Study Phase: Phase 3
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Radiation
Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Enrollment Status: Completed
Publish Date: April 08, 2026
Intervention Type: Drug, Behavioral, Other, Procedure
Study Drug: 6-Mercaptopurine
Study Phase: Phase 3
Umbrella Long-Term Follow-Up Protocol
Umbrella Long-Term Follow-Up Protocol
Enrollment Status: Active_not_recruiting
Publish Date: April 06, 2026
Intervention Type: Procedure, Other
View 7 Less Clinical Trials

15 Total Publications

Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis.
Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis.
Journal: Cancer medicine
Published: October 07, 2022
Similar Doctors
Expertise in
24
conditions
Dr. Leslie Andritsos
Hematology
Expertise in
24
conditions
Dr. Leslie Andritsos
Hematology
Referral may be required

Cancer Center Pharmacy

Albuquerque, NM 
 (2.2 miles away)
505-272-4946
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leslie Andritsos is a Hematologist practicing medicine in Albuquerque, New Mexico. Dr. Andritsos is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Hairy Cell Leukemia (HCL), Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Bone Marrow Transplant, and Splenectomy.

Expertise in
15
conditions
Dr. Matthew Fero
Hematology | Oncology
Expertise in
15
conditions
Dr. Matthew Fero
Hematology | Oncology
Referral may be required

Cancer Center Pharmacy

Albuquerque, NM 
 (2.2 miles away)
206-288-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Fero is a Hematologist and an Oncologist practicing medicine in Albuquerque, New Mexico. Dr. Fero is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Multiple Myeloma, Classical Hodgkin Lymphoma, and Chronic Lymphocytic Leukemia (CLL).

Expertise in
20
conditions
Dr. Olivier Rixe
Hematology | Oncology
Expertise in
20
conditions
Dr. Olivier Rixe
Hematology | Oncology
Referral may be required

New Mexico Cancer Care Associates

490A W Zia Rd, 
Santa Fe, NM 
 (55.3 miles away)
505-913-8900
Languages Spoken:
English
See accepted insurances

Olivier Rixe is a Hematologist and an Oncologist practicing medicine in Santa Fe, New Mexico. Dr. Rixe is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Melanoma, Glioblastoma, Astrocytoma, and Glioma.

Frequently Asked Questions about Dr. John Kuttesch

How do I make an appointment with Dr. John Kuttesch?

You can book an appointment with Dr. John Kuttesch by calling their office at 505-272-4461. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John Kuttesch a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John Kuttesch is classified as an Experienced expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John Kuttesch specialize in?

While Dr. John Kuttesch is a Hematology, they have specific expertise in Acute Lymphoblastic Leukemia (ALL), Leukemia, and Embryonal Tumor with Multilayered Rosettes. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. John Kuttesch participate in research or clinical trials?

Yes. Dr. John Kuttesch has published 15 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Dr. John Kuttesch's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kuttesch's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile